Active Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Active Biotech şirketinin toplam hissedar öz sermayesi SEK1.4M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK14.9M ve SEK13.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 6.20m
Eşitlik	SEK 1.40m
Toplam yükümlülükler	SEK 13.50m
Toplam varlıklar	SEK 14.90m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BTPC 'nin kısa vadeli varlıkları ( SEK10.7M ) kısa vadeli yükümlülüklerini ( SEK11.5M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: BTPC şirketinin kısa vadeli varlıkları ( SEK10.7M ) uzun vadeli yükümlülüklerini ( SEK2.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BTPC borçsuzdur.

Borcun Azaltılması: BTPC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BTPC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BTPC un, serbest nakit akışı her yıl % 5.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Active Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New major risk - Financial position

New major risk - Market cap size

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

New minor risk - Profitability

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Chairman of the Board recently bought €26k worth of stock

New 90-day high: €0.25

Active Biotech Receive Milestone Payment from Neotx

Active Biotech AB Appoints Elaine Sullivan as A Director

Earnings released

New 90-day high - €0.32

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin